Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-041032
Filing Date
2021-06-16
Accepted
2021-06-16 17:59:55
Documents
1
Period of Report
2021-06-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 25934
  Complete submission text file 0001209191-21-041032.txt   28017
Mailing Address 1134 KLINE STREET LA JOLLA CA 92037
Business Address 1134 KLINE STREET LA JOLLA CA 92037 8583482180
Avalon Ventures XI, L.P. (Reporting) CIK: 0001652901 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-40475 | Film No.: 211022623

Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Issuer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 11099 NORTH TORREY PINES ROAD, SUITE 290 LA JOLLA CA 92037
Business Address 11099 NORTH TORREY PINES ROAD, SUITE 290 LA JOLLA CA 92037 858-750-4700
Avalon BioVentures SPV I, L.P. (Reporting) CIK: 0001844550 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-40475 | Film No.: 211022622